Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Amino Acid Loss during Continuous Venovenous Hemofiltration in Critically Ill Patients.

Stapel SN, de Boer RJ, Thoral PJ, Vervloet MG, Girbes ARJ, Oudemans-van Straaten HM.

Blood Purif. 2019 Jul 10:1-9. doi: 10.1159/000500998. [Epub ahead of print]

PMID:
31291614
Free Article
2.

Chronic kidney disease-mineral and bone disorder: changing insights form changing parameters?

Vervloet MG.

Nephrol Dial Transplant. 2019 Jun 10. pii: gfz113. doi: 10.1093/ndt/gfz113. [Epub ahead of print] No abstract available.

PMID:
31180483
3.

Most exposed: the endothelium in chronic kidney disease.

Vila Cuenca M, Hordijk PL, Vervloet MG.

Nephrol Dial Transplant. 2019 Apr 8. pii: gfz055. doi: 10.1093/ndt/gfz055. [Epub ahead of print]

PMID:
31071222
4.

Pre-analytical stability of FGF23 with the contemporary immunoassays.

Dirks NF, Smith ER, van Schoor NM, Vervloet MG, Ackermans MT, de Jonge R, Heijboer AC.

Clin Chim Acta. 2019 Jun;493:104-106. doi: 10.1016/j.cca.2019.02.032. Epub 2019 Mar 1.

PMID:
30826370
5.

Magnesium: A Magic Bullet for Cardiovascular Disease in Chronic Kidney Disease?

Leenders NHJ, Vervloet MG.

Nutrients. 2019 Feb 22;11(2). pii: E455. doi: 10.3390/nu11020455. Review.

6.

The Bone-Vasculature Axis: Calcium Supplementation and the Role of Vitamin K.

Wasilewski GB, Vervloet MG, Schurgers LJ.

Front Cardiovasc Med. 2019 Feb 5;6:6. doi: 10.3389/fcvm.2019.00006. eCollection 2019. Review.

7.

Joint association of vitamins D and K status with long-term outcomes in stable kidney transplant recipients.

van Ballegooijen AJ, Beulens JWJ, Keyzer CA, Navis GJ, Berger SP, de Borst MH, Vervloet MG, Bakker SJL.

Nephrol Dial Transplant. 2019 Feb 12. doi: 10.1093/ndt/gfy399. [Epub ahead of print]

PMID:
30753729
8.

Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults.

van Ballegooijen AJ, Beulens JWJ, Schurgers LJ, de Koning EJ, Lips P, van Schoor NM, Vervloet MG.

Nutrients. 2019 Jan 22;11(2). pii: E231. doi: 10.3390/nu11020231.

9.

Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study.

Adema AY, de Roij van Zuijdewijn CLM, Hoenderop JG, de Borst MH, Ter Wee PM, Heijboer AC, Vervloet MG; NIGRAM consortium,.

BMC Nephrol. 2018 Nov 15;19(1):327. doi: 10.1186/s12882-018-1114-z.

10.

Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability.

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG.

J Am Heart Assoc. 2018 Sep 4;7(17):e008776. doi: 10.1161/JAHA.118.008776. Erratum in: J Am Heart Assoc. 2018 Oct 2;7(19):e02709.

11.

The role of kidney transplantation and phosphate binder use in vitamin K status.

Jansz TT, Neradova A, van Ballegooijen AJ, Verhaar MC, Vervloet MG, Schurgers LJ, van Jaarsveld BC.

PLoS One. 2018 Aug 30;13(8):e0203157. doi: 10.1371/journal.pone.0203157. eCollection 2018.

12.

[Renal complications of lithium use: to cease or to continue?]

Beunders AJM, Hillegers MHJ, Regeer EJ, Vervloet MG, Gaillard CAJM, Dols A.

Ned Tijdschr Geneeskd. 2018 May 29;162. pii: D2683. Dutch.

PMID:
30040291
13.

FGF23 impairs peripheral microvascular function in renal failure.

Verkaik M, Juni RP, van Loon EPM, van Poelgeest EM, Kwekkeboom RFJ, Gam Z, Richards WG, Ter Wee PM, Hoenderop JG, Eringa EC, Vervloet MG; NIGRAM Consortium.

Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1414-H1424. doi: 10.1152/ajpheart.00272.2018. Epub 2018 Jul 20.

PMID:
30028196
14.

The interrelation between FGF23 and glucose metabolism in humans.

Ursem SR, Vervloet MG, Büttler RM, Ackermans MT, Oosterwerff MM, Eekhoff EMV, Lips P, Serlie MJ, la Fleur SE, Heijboer AC.

J Diabetes Complications. 2018 Sep;32(9):845-850. doi: 10.1016/j.jdiacomp.2018.06.013. Epub 2018 Jun 27.

PMID:
29996975
15.

Hyperphosphataemia: which phosphate binder?

Vervloet MG.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1091-1093. doi: 10.1093/ndt/gfy091. No abstract available.

PMID:
29982717
16.

Routine hemodialysis induces a decline in plasma magnesium concentration in most patients: a prospective observational cohort study.

Leenders NHJ, van Ittersum FJ, Hoekstra T, Hoenderop JGJ, Vervloet MG.

Sci Rep. 2018 Jul 6;8(1):10256. doi: 10.1038/s41598-018-28629-x.

17.

Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam.

Chen H, Lips P, Vervloet MG, van Schoor NM, de Jongh RT.

Osteoporos Int. 2018 Sep;29(9):2129-2138. doi: 10.1007/s00198-018-4592-8. Epub 2018 Jun 15.

18.

Clinical utility of bone markers in various diseases.

Vlot MC, den Heijer M, de Jongh RT, Vervloet MG, Lems WF, de Jonge R, Obermayer-Pietsch B, Heijboer AC.

Bone. 2018 Sep;114:215-225. doi: 10.1016/j.bone.2018.06.011. Epub 2018 Jun 18. Review.

PMID:
29920402
19.

Fluid balance-adjusted creatinine at initiation of continuous venovenous hemofiltration and mortality. A post-hoc analysis of a multicenter randomized controlled trial.

Stads S, Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, Vervloet MG, Beishuizen A, Girbes ARJ, Ter Wee PM, Gommers D, Groeneveld ABJ, Oudemans-van Straaten HM; CASH study group.

PLoS One. 2018 Jun 6;13(6):e0197301. doi: 10.1371/journal.pone.0197301. eCollection 2018.

20.

Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model.

Vila Cuenca M, Keuning ED, Talhout W, Paauw NJ, van Ittersum FJ, Ter Wee PM, Beelen RHJ, Vervloet MG, Ferrantelli E.

Int Urol Nephrol. 2018 Jun;50(6):1151-1161. doi: 10.1007/s11255-018-1872-3. Epub 2018 May 4.

21.

Stabilization of cell-cell junctions by active vitamin D ameliorates uraemia-induced loss of human endothelial barrier function.

Vila Cuenca M, van Bezu J, Beelen RHJ, Vervloet MG, Hordijk PL.

Nephrol Dial Transplant. 2019 Feb 1;34(2):252-264. doi: 10.1093/ndt/gfy111.

PMID:
29718431
22.

The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine.

Dirks NF, Ackermans MT, Lips P, de Jongh RT, Vervloet MG, de Jonge R, Heijboer AC.

Nutrients. 2018 Apr 13;10(4). pii: E482. doi: 10.3390/nu10040482. Review.

23.

High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes.

Verkaik M, Oranje M, Abdurrachim D, Goebel M, Gam Z, Prompers JJ, Helmes M, Ter Wee PM, van der Velden J, Kuster DW, Vervloet MG, Eringa EC; NIGRAM consortium.

Physiol Rep. 2018 Apr;6(7):e13591. doi: 10.14814/phy2.13591.

24.

Prevention and treatment of hyperphosphatemia in chronic kidney disease.

Vervloet MG, van Ballegooijen AJ.

Kidney Int. 2018 May;93(5):1060-1072. doi: 10.1016/j.kint.2017.11.036. Epub 2018 Mar 23. Review.

PMID:
29580635
25.

Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.

Schumacher SP, Schurgers LJ, Vervloet MG, Neradova A.

Nephrology (Carlton). 2019 Feb;24(2):221-226. doi: 10.1111/nep.13245. Epub 2018 Apr 6.

26.

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20.

PMID:
29459980
27.

Effects of Oral Paricalcitol and Calcitriol Treatment on Peritoneal Membrane Characteristics of Peritoneal Dialysis Patients - A Pilot Study.

Farhat K, Stavenuiter AWD, Vervloet MG, Ter Wee PM, Beelen RHJ, van Ittersum FJ.

Perit Dial Int. 2018 May-Jun;38(3):220-228. doi: 10.3747/pdi.2017.00150. Epub 2018 Jan 31.

PMID:
29386308
28.

Myocardial contrast echocardiography in mice: technical and physiological aspects.

Verkaik M, van Poelgeest EM, Kwekkeboom RFJ, Ter Wee PM, van den Brom CE, Vervloet MG, Eringa EC.

Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H381-H391. doi: 10.1152/ajpheart.00242.2017. Epub 2017 Nov 3. Review.

29.

Oxidation of PTH: in vivo feature or effect of preanalytical conditions?

Ursem SR, Vervloet MG, Hillebrand JJG, de Jongh RT, Heijboer AC.

Clin Chem Lab Med. 2018 Jan 26;56(2):249-255. doi: 10.1515/cclm-2017-0313.

PMID:
28809747
30.

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006. Review. Erratum in: Kidney Int. 2017 Dec;92(6):1558.

31.

Circulating markers of bone turnover.

Vervloet MG, Brandenburg VM; CKD-MBD working group of ERA-EDTA.

J Nephrol. 2017 Oct;30(5):663-670. doi: 10.1007/s40620-017-0408-8. Epub 2017 May 13. Review.

32.

Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study.

Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG.

BMC Nephrol. 2017 May 2;18(1):149. doi: 10.1186/s12882-017-0560-3.

33.
34.

Magnesium-based interventions for normal kidney function and chronic kidney disease.

Massy ZA, Nistor I, Apetrii M, Brandenburg VM, Bover J, Evenepoel P, Goldsmith D, Mazzaferro S, Urena-Torres P, Vervloet MG, Cozzolino M, Covic A, Era-Edta OB.

Magnes Res. 2016 Apr 1;29(4):126-140. doi: 10.1684/mrh.2016.0412. Review.

PMID:
28007671
35.

The role of phosphate in kidney disease.

Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group.

Nat Rev Nephrol. 2017 Jan;13(1):27-38. doi: 10.1038/nrneph.2016.164. Epub 2016 Nov 21. Review.

PMID:
27867189
36.

Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.

Humalda JK, Seiler-Muler S, Kwakernaak AJ, Vervloet MG, Navis G, Fliser D, Heine GH, de Borst MH.

Medicine (Baltimore). 2016 Nov;95(46):e5003.

37.

Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.

Keyzer CA, van Breda GF, Vervloet MG, de Jong MA, Laverman GD, Hemmelder MH, Janssen WM, Lambers Heerspink HJ, Kwakernaak AJ, Bakker SJ, Navis G, de Borst MH; Holland Nephrology Study (HONEST) Network.

J Am Soc Nephrol. 2017 Apr;28(4):1296-1305. doi: 10.1681/ASN.2016040407. Epub 2016 Nov 17.

38.

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).

Adema AY, de Jong MA, de Borst MH, Ter Wee PM, Vervloet MG; NIGRAM Consortium.

Nephron. 2016;134(4):215-220. Epub 2016 Jul 22.

39.

Serum sclerostin: relation with mortality and impact of hemodiafiltration.

Lips L, de Roij van Zuijdewijn CLM, Ter Wee PM, Bots ML, Blankestijn PJ, van den Dorpel MA, Fouque D, de Jongh R, Pelletier S, Vervloet MG, Nubé MJ, Grooteman MPC.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1217-1223. doi: 10.1093/ndt/gfw246.

PMID:
27342581
40.

Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.

de Jong MA, Mirkovic K, Mencke R, Hoenderop JG, Bindels RJ, Vervloet MG, Hillebrands JL, van den Born J, Navis G, de Borst MH; NIGRAM consortium.

Nephrol Dial Transplant. 2017 Jan 1;32(1):73-80. doi: 10.1093/ndt/gfw105.

PMID:
27220755
41.

Abdominal aortic calcification in patients with CKD.

Peeters MJ, van den Brand JA, van Zuilen AD, Koster Y, Bots ML, Vervloet MG, Blankestijn PJ, Wetzels JF; MASTERPLAN Study Group.

J Nephrol. 2017 Feb;30(1):109-118. doi: 10.1007/s40620-015-0260-7. Epub 2016 Mar 22.

42.

The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis.

Ferrantelli E, Liappas G, Vila Cuenca M, Keuning ED, Foster TL, Vervloet MG, Lopéz-Cabrera M, Beelen RH.

Kidney Int. 2016 Mar;89(3):625-35. doi: 10.1016/j.kint.2015.12.005. Epub 2016 Jan 8.

PMID:
26880457
43.

Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.

Adema AY, van Ittersum FJ, Hoenderop JG, de Borst MH, Nanayakkara PW, Ter Wee PM, Heijboer AC, Vervloet MG; NIGRAM consortium.

PLoS One. 2016 Jan 25;11(1):e0144121. doi: 10.1371/journal.pone.0144121. eCollection 2016.

44.

Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?

Evenepoel P, Vervloet MG.

Kidney Int. 2016 Jan;89(1):21-3. doi: 10.1016/j.kint.2015.11.006.

PMID:
26759042
45.

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis.

Stavenuiter AW, Farhat K, Vila Cuenca M, Schilte MN, Keuning ED, Paauw NJ, ter Wee PM, Beelen RH, Vervloet MG.

Biomed Res Int. 2015;2015:468574. doi: 10.1155/2015/468574. Epub 2015 Oct 29.

46.

Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis.

Humalda JK, Riphagen IJ, Assa S, Hummel YM, Westerhuis R, Vervloet MG, Voors AA, Navis G, Franssen CF, de Borst MH; NIGRAM Consortium.

Nephrol Dial Transplant. 2016 Sep;31(9):1494-501. doi: 10.1093/ndt/gfv393. Epub 2015 Nov 24.

PMID:
26602863
47.

Serum Magnesium and Sudden Death in European Hemodialysis Patients.

de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, Blankestijn PJ, Steppan S, Büchel J, Groenwold RH, Brandenburg V, van den Dorpel MA, Ter Wee PM, Nubé MJ, Vervloet MG.

PLoS One. 2015 Nov 23;10(11):e0143104. doi: 10.1371/journal.pone.0143104. eCollection 2015.

48.

Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure.

Pulskens WP, Verkaik M, Sheedfar F, van Loon EP, van de Sluis B, Vervloet MG, Hoenderop JG, Bindels RJ; NIGRAM Consortium.

PLoS One. 2015 Nov 13;10(11):e0142510. doi: 10.1371/journal.pone.0142510. eCollection 2015.

49.

Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

Brandenburg VM, Kleber ME, Vervloet MG, Larsson TE, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H.

Atherosclerosis. 2015 Oct;242(2):483-9. doi: 10.1016/j.atherosclerosis.2015.08.017. Epub 2015 Aug 13.

PMID:
26298739
50.

α-Klotho is unstable in human urine.

Adema AY, Vervloet MG, Blankenstein MA, Heijboer AC.

Kidney Int. 2015 Dec;88(6):1442-1444. doi: 10.1038/ki.2015.238. Epub 2015 Aug 5.

PMID:
26244922

Supplemental Content

Loading ...
Support Center